文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

长效注射PrEP使用者的HIV RNA与抗原抗体检测真实世界研究

Real-world HIV RNA and Antigen/Antibody Testing Among People Who Use Long-acting Injectable Preexposure Prophylaxis.
PubMed 文献 · Clin Infect Dis · 2025-01-01

本研究利用HealthVerity数据库开展队列研究,评估使用CAB-LA PrEP者的HIV检测利用情况。在384名同时接受HIV Ag/Ab和RNA检测的使用者中,未发现确诊的突破性HIV感染或LEVI综合征,也未发现RNA检测较Ag/Ab检测更早诊断HIV。

要点

  • 384名CAB-LA PrEP使用者中未发现确诊突破性HIV感染或LEVI综合征。
  • 4例Ag/Ab或RNA阳性中,1例为CAB-LA前感染,1例可能假RNA阳性,1例可能假Ag/Ab阳性,1例Ag/Ab阳性结果不确定。
  • 未发现RNA检测较Ag/Ab检测单独使用能更早诊断HIV。

核心结论

  • 在该真实世界队列中,注射PrEP使用初始3-7个月内突破性HIV感染或LEVI综合征的频率较低。
  • 有必要持续评估HIV RNA检测在CAB-LA PrEP使用期间监测中的附加价值。

研究设计与样本

  • 队列研究,使用HealthVerity数据库,评估使用CAB-LA PrEP者的HIV检测利用情况。
  • 纳入384名同时接受HIV Ag/Ab和RNA检测的CAB-LA PrEP使用者,中位随访时间4.2个月。

主要发现

  • 384名使用者中发现1对不一致结果:Ag/Ab阴性(-)且RNA阳性(+),以及1对Ag/Ab(+)且RNA(-)。
  • 4名Ag/Ab或RNA阳性使用者中,1例为CAB-LA启动前感染(Ag/Ab(+)且RNA(+)),1例可能假RNA(+),1例可能假Ag/Ab(+),1例因随访不足Ag/Ab(+)结果不确定。
  • 未发现确诊的突破性HIV感染或LEVI综合征,也未发现RNA检测较Ag/Ab检测单独使用能更早诊断HIV。

关键数值与推荐

  • 2021年美国CDC PrEP指南推荐在CAB-LA启动和随访时同时进行HIV抗原/抗体(Ag/Ab)和RNA检测。

临床怎么用

  • 根据2021年CDC PrEP指南,CAB-LA启动和随访时应同时进行HIV Ag/Ab和RNA检测。
  • 真实世界数据显示初始3-7个月突破性感染或LEVI综合征频率较低,但需持续评估RNA检测的附加价值。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: People who use long-acting injectable cabotegravir (CAB-LA) for preexposure prophylaxis (PrEP) can have ambiguous human immunodeficiency virus (HIV) test results if HIV is acquired during its use. The 2021 Centers for Disease Control and Prevention PrEP guidelines recommend both HIV antigen/antibody (Ag/Ab) and RNA testing at CAB-LA initiation and follow-up. METHODS: We conducted a cohort study using the HealthVerity database to evaluate the utilization of HIV testing among people who use CAB-LA PrEP. We identified and adjudicated HIV Ag/Ab and RNA tests with a positive result, and estimated the incidence of breakthrough HIV infection or long-acting early viral inhibition (LEVI) syndrome. Testing agreement, false-positive test rates, and positive predictive value were explored. RESULTS: Among 384 people who use CAB-LA PrEP with both HIV Ag/Ab and RNA testing with a median follow-up time of 4.2 months, we found 1 discordant pair with Ag/Ab negative (-) and RNA positive (+), and 1 with Ag/Ab(+) and RNA(-). Among 4 users with a positive Ag/Ab or RNA test, we identified 1 who acquired HIV before CAB-LA initiation with both Ag/Ab(+) and RNA(+), 1 likely false RNA(+), 1 likely false Ag/Ab(+), and 1 inconclusive Ag/Ab(+) due to insufficient follow-up. We identified no persons with confirmed breakthrough HIV infection or LEVI syndrome, or with RNA testing resulting in an earlier HIV diagnosis compared with Ag/Ab testing alone. CONCLUSIONS: The frequency of breakthrough HIV infection or LEVI syndrome in this real-world cohort was low during initial 3-7 months of injectable PrEP use. Ongoing assessment of the added value of HIV RNA testing for monitoring during CAB-LA PrEP use is warranted.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Zhu W, Delaney K, Huang YA, et al. Real-world HIV RNA and Antigen/Antibody Testing Among People Who Use Long-acting Injectable Preexposure Prophylaxis. Clin Infect Dis. 2025. PMID: 40176250. doi:10.1093/cid/ciaf173

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。